Relation of myeloperoxidase promoter polymorphism and long‐term hormone replacement therapy to oxidized low‐density lipoprotein autoantibodies in postmenopausal women

References

• Hodis H. N., Mack W. J., Lobo R. A., Shoupe D., Sevanian A., Mahrer P. R., et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Ann Intern Med 2001; 135: 939–53
   PubMed Web of Science ®Google Scholar
• Nabulsi A. A., Folsom A. R., White A., Patsch W., Heiss G., Wu K. K., et al. Association of hormone‐replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1993; 328: 1069–75
   PubMed Web of Science ®Google Scholar
• Punnonen R. H., Jokela H. A., Dastidar P. S., Nevala M., Laippala P. J. Combined oestrogen‐progestin replacement therapy prevents atherosclerosis in postmenopausal women. Maturitas 1995; 21: 179–87
   PubMed Web of Science ®Google Scholar
• Ross R. K., Paganini‐Hill A., Mack T. M., Arthur M., Henderson B. E. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet 1981; 1: 858–60
   PubMed Web of Science ®Google Scholar
• Grady D., Herrington D., Bittner V., Blumenthal R., Davidson M., Hlatky M., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow‐up (HERS II). JAMA 2002; 288: 49–57
   PubMed Web of Science ®Google Scholar
• Rossouw J. E., Anderson G. L., Prentice R. L., LaCroix A. Z., Kooperberg C., Stefanick M. L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33
   PubMed Web of Science ®Google Scholar
• Jokela H., Dastidar P., Rontu R., Salomaki A., Teisala K., Lehtimaki T., et al. Effects of long‐term estrogen replacement therapy versus combined hormone replacement therapy on nitric oxide‐dependent vasomotor function. J Clin Endocrinol Metab 2003; 88: 4348–54
   PubMedGoogle Scholar
• Lehtimaki T., Dastidar P., Jokela H., Koivula T., Lehtinen S., Ehnholm C., et al. Effect of long‐term hormone replacement therapy on atherosclerosis progression in postmenopausal women relates to functional apolipoprotein e genotype. J Clin Endocrinol Metab 2002; 87: 4147–53
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115–26
   PubMed Web of Science ®Google Scholar
• Lehtimaki T., Lehtinen S., Solakivi T., Nikkila M., Jaakkola O., Jokela H., et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 1999; 19: 23–7
   PubMed Web of Science ®Google Scholar
• Salonen J. T., Yla‐Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883–7
   PubMed Web of Science ®Google Scholar
• Puurunen M., Manttari M., Manninen V., Tenkanen L., Alfthan G., Ehnholm C., et al. Antibody against oxidized low‐density lipoprotein predicting myocardial infarction. Arch Intern Med 1994; 154: 2605–9
   PubMedGoogle Scholar
• Klebanoff S. J. Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med 1980; 93: 480–9
   PubMed Web of Science ®Google Scholar
• Daugherty A., Dunn J. L., Rateri D. L., Heinecke J. W. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994; 94: 437–44
   PubMed Web of Science ®Google Scholar
• Heinecke J. W. Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders. J Lab Clin Med 1999; 133: 321–5
   PubMed Web of Science ®Google Scholar
• Hazell L. J., Arnold L., Flowers D., Waeg G., Malle E., Stocker R. Presence of hypochlorite‐modified proteins in human atherosclerotic lesions. J Clin Invest 1996; 97: 1535–44
   PubMed Web of Science ®Google Scholar
• Hazen S. L., Heinecke J. W. 3‐Chlorotyrosine, a specific marker of myeloperoxidase‐catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 1997; 99: 2075–81
   PubMed Web of Science ®Google Scholar
• Pentikainen M. O., Oorni K., Kovanen P. T. Myeloperoxidase and hypochlorite, but not copper ions, oxidize heparin‐bound LDL particles and release them from heparin. Arterioscler Thromb Vasc Biol 2001; 21: 1902–8
   PubMedGoogle Scholar
• Buffon A., Biasucci L. M., Liuzzo G., D'Onofrio G., Crea F., Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002; 347: 5–12
   PubMed Web of Science ®Google Scholar
• Zhang C., Reiters C., Eiserich J. P., Boersma B., Parks D. A., Beckman J. S., et al. L‐arginine chlorination products inhibit endothelial nitric oxide production. J Biol Chem 2001; 276: 27159–65
   PubMed Web of Science ®Google Scholar
• Brennan M. L., Penn M. S., Van Lente F., Nambi V., Shishehbor M. H., Aviles R. J., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349: 1595–604
   PubMed Web of Science ®Google Scholar
• Jansson G. Oestrogen‐induced enhancement of myeloperoxidase activity in human polymorphonuclear leukocytes: a possible cause of oxidative stress in inflammatory cells. Free Radic Res Commun 1991; 14: 195–208
   PubMed Web of Science ®Google Scholar
• Santanam N., Shern‐Brewer R., McClatchey R., Castellano P. Z., Murphy A. A., Voelkel S., et al. Estradiol as an antioxidant: incompatible with its physiological concentrations and function. J Lipid Res 1998; 39: 2111–8
   PubMed Web of Science ®Google Scholar
• Bekesi G., Kakucs R., Varbiro S., Feher J., Pazmany T., Magyar Z., et al. Induced myeloperoxidase activity and related superoxide inhibition during hormone replacement therapy. BJOG 2001; 108: 474–81
   PubMed Web of Science ®Google Scholar
• Piedrafita F. J., Molander R. B., Vansant G., Orlova E. A., Pfahl M., Reynolds W. F. An Alu element in the myeloperoxidase promoter contains a composite SP1‐thyroid hormone‐retinoic acid response element. J Biol Chem 1996; 271: 14412–20
   PubMed Web of Science ®Google Scholar
• Reynolds W. F., Chang E., Douer D., Ball E. D., Kanda V. An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood 1997; 90: 2730–7
   PubMed Web of Science ®Google Scholar
• Nikpoor B., Turecki G., Fournier C., Théroux P., Rouleau G. A. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French‐Canadians. Am Heart J 2001; 142: 336–9
   PubMed Web of Science ®Google Scholar
• Pecoits‐Filho R., Stenvinkel P., Marchlewska A., Heimburger O., Barany P., Hoff C. M., et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end‐stage renal disease patients. Kidney Int Suppl 2003; S172–6
   PubMedGoogle Scholar
• Reynolds W. F., Rhees J., Maciejewski D., Paladino T., Sieburg H., Maki R. A., et al. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol 1999; 155: 31–41
   PubMed Web of Science ®Google Scholar
• Nagra R. M., Becher B., Tourtellotte W. W., Antel J. P., Gold D., Paladino T., et al. Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol 1997; 78: 97–107
   PubMed Web of Science ®Google Scholar
• Reynolds W. F., Stegeman C. A., Tervaert J. W. −463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO‐ANCA‐associated vasculitis. Clin Immunol 2002; 103: 154–60
   PubMed Web of Science ®Google Scholar
• Koivu T. A., Dastidar P., Jokela H., Nikkari S. T., Jaakkola O., Koivula T., et al. The relation of oxidized LDL autoantibodies and long‐term hormone replacement therapy to ultrasonographically assessed atherosclerotic plaque quantity and severity in postmenopausal women. Atherosclerosis 2001; 157: 471–9
   PubMedGoogle Scholar
• Makela R., Dastidar P., Jokela H., Saarela M., Punnonen R., Lehtimaki T. Effect of long‐term hormone replacement therapy on atherosclerosis progression in postmenopausal women relates to myeloperoxidase promoter polymorphism. J Clin Endocrinol Metab 2003; 88: 3823–8
   PubMedGoogle Scholar
• Furberg C. D., Byington R. P., Borhani N. A. Multicenter isradipine diuretic atherosclerosis study (MIDAS). Design features. The Midas Research Group. Am J Med 1989; 86: 37–9
   PubMed Web of Science ®Google Scholar
• London S. J., Lehman T. A., Taylor J. A. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 1997; 57: 5001–3
   PubMed Web of Science ®Google Scholar
• Nquven T., Warnig R. Improved method for separation of total HDL cholesterol and subclasses. Clinical chemistry 1989; 35: 1086
   Google Scholar
• Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low‐density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502
   PubMed Web of Science ®Google Scholar
• Riepponen P., Marniemi J., Rautaoja T. Immunoturbidimetric determination of apolipoproteins A‐1 and B in serum. Scand J Clin Lab Invest 1987; 47: 739–44
   PubMed Web of Science ®Google Scholar
• Cascorbi I., Henning S., Brockmoller J., Gephart J., Meisel C., Muller J. M., et al. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant −463A of the myeloperoxidase gene. Cancer Res 2000; 60: 644–9
   PubMed Web of Science ®Google Scholar
• Stampfer M. J., Colditz G. A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47–63
   PubMed Web of Science ®Google Scholar
• Gabriel S. R., Carmona L., Roque M., Sanchez G. L., Bonfill X. Hormone replacement therapy for preventing cardiovascular disease in post‐menopausal women. Cochrane Database Syst Rev 2005, CD002229
   PubMedGoogle Scholar
• Mikkola T. S., Clarkson T. B. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002; 53: 605–19
   PubMed Web of Science ®Google Scholar
• Baker L., Meldrum K. K., Wang M., Sankula R., Vanam R., Raiesdana A., et al. The role of estrogen in cardiovascular disease. J Surg Res 2003; 115: 325–44
   PubMed Web of Science ®Google Scholar
• Stork S., Van Der Schouw Y. T., Grobbee D. E., Bots M. L. Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. Trends Endocrinol Metab 2004; 15: 66–72
   PubMed Web of Science ®Google Scholar
• Miyagawa K., Rosch J., Stanczyk F., Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 1997; 3: 324–7
   PubMed Web of Science ®Google Scholar
• Xing D., Miller A., Novak L., Rocha R., Chen Y. F., Oparil S. Estradiol and progestins differentially modulate leukocyte infiltration after vascular injury. Circulation 2004; 109: 234–41, Epub 2003 Dec 29
   PubMed Web of Science ®Google Scholar
• Zhu X., Bonet B., Gillenwater H., Knopp R. H. Opposing effects of estrogen and progestins on LDL oxidation and vascular wall cytotoxicity: implications for atherogenesis. Proc Soc Exp Biol Med 1999; 222: 214–21
   PubMedGoogle Scholar
• Zhu X. D., Bonet B., Knopp R. H. 17Beta‐estradiol, progesterone, and testosterone inversely modulate low‐density lipoprotein oxidation and cytotoxicity in cultured placental trophoblast and macrophages. Am J Obstet Gynecol 1997; 177: 196–209
   PubMed Web of Science ®Google Scholar
• Arteaga E., Rojas A., Villaseca P., Bianchi M., Arteaga A., Duran D. In vitro effect of estradiol, progesterone, testosterone, and of combined estradiol/progestins on low density lipoprotein (LDL) oxidation in postmenopausal women. Menopause 1998; 5: 16–23
   PubMed Web of Science ®Google Scholar
• McManus J., McEneny J., Young I. S., Thompson W. The effect of various oestrogens and progestogens on the susceptibility of low density lipoproteins to oxidation in vitro. Maturitas 1996; 25: 125–31
   PubMed Web of Science ®Google Scholar
• McManus J., McEneny J., Thompson W., Young I. S. The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women. Atherosclerosis 1997; 135: 73–81
   PubMed Web of Science ®Google Scholar
• Sack M. N., Rader D. J., Cannon R. O, 3rd. Oestrogen and inhibition of oxidation of low‐density lipoproteins in postmenopausal women. Lancet 1994; 343: 269–70
   PubMed Web of Science ®Google Scholar
• Wakatsuki A., Ikenoue N., Sagara Y. Effects of estrogen on susceptibility to oxidation of low‐density and high‐density lipoprotein in postmenopausal women. Maturitas 1998; 28: 229–34
   PubMed Web of Science ®Google Scholar
• Heikkinen A. M., Niskanen L., Yla‐Herttuala S., Luoma J., Tuppurainen M. T., Komulainen M., et al. Postmenopausal hormone replacement therapy and autoantibodies against oxidized LDL. Maturitas 1998; 29: 155–61
   PubMedGoogle Scholar
• Hermenegildo C., Garcia‐Martinez M. C., Tarin J. J., Llacer A., Cano A. The effect of oral hormone replacement therapy on lipoprotein profile, resistance of LDL to oxidation and LDL particle size. Maturitas 2001; 38: 287–95
   PubMedGoogle Scholar
• Kabutomori O., Yanagihara T., Iwatani Y., Kawarazaki A., Kabutomori M. Sex difference in myeloperoxidase activity of neutrophils. Am J Hematol 1999; 60: 312–3
   PubMedGoogle Scholar
• Bekesi G., Magyar Z., Kakucs R., Sprintz D., Kocsis I., Szekacs B., et al. Changes in the myeloperoxidase activity of human neutrophilic granulocytes and the amount of enzyme deriving from them under the effect of estrogen. Orv Hetil 1999; 140: 1625–30
   PubMedGoogle Scholar
• Asselbergs F. W., Reynolds W. F., Cohen‐Tervaert J. W., Jessurun G. A., Tio R. A. Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med 2004; 116: 429–30
   PubMed Web of Science ®Google Scholar
• Kumar A. P., Piedrafita F. J., Reynolds W. F. Peroxisome proliferator‐activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen‐dependent mechanism involving the −463GA promoter polymorphism. J Biol Chem 2004; 279: 8300–15, Epub 2003 Dec 10
   PubMed Web of Science ®Google Scholar
• Reynolds W. F., Hiltunen M., Pirskanen M., Mannermaa A., Helisalmi S., Lehtovirta M., et al. MPO and APOEepsilon4 polymorphisms interact to increase risk for AD in Finnish males. Neurology 2000; 55: 1284–90
   PubMedGoogle Scholar